UK court OKs Herceptin biosimilar

Share this article:

Biosimilar Herceptin is coming to the UK. Bloomberg reports that a London judge declared two of Roche's patents invalid.

Herceptin patents were set to expire in July but Bloomberg notes this lawsuit was over two additional patents that applied to dosing and composition.

Roche has been preparing for a Herceptin biosimilar for some time, including landing regulatory approval for breast cancer treatment Kadcyla.

Dubbed “super Herceptin,” this treatment combines blockbuster Herceptin with a taxane chemotherapy, as well as a third chemical developed by San Francisco-based ImmunoGen and licensed by Genentech that binds the medicines together.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions